Value of Lab Medicine: Technology is Changing the Delivery of Care
Tracking # 20-1139532
Price not reported
There are no ratings for this course
Learn moreCourse overview
Technological improvements have led to new and better methods for identifying and diagnosing medical conditions, while streamlining the delivery of patient care and improving outcomes. These advancements have also created challenges for laboratories and payers alike, as labs often need to modify their operations to accommodate the new technologies, while insurers struggle with applying existing coverage and payment policies to the tests. The second in a series, this webinar will use case studies involving cardiac troponin and pharmacogenetics to examine the clinical and operational aspects of implementing a novel technology, provide tools for measuring whether a new method improves the delivery of patient care, and evaluate the financial challenges of a new test for the laboratory, patient, and insurer. The speakers will also offer practical strategies for addressing these management and fiscal issues.
Subject areas
This course counts toward the state boards and subject areas below.
American Board of Clinical Chemistry
Clinical Chemistry Diplomate
Molecular Diagnostics Diplomate
Toxicological Chemistry Diplomate
Florida Board of Clinical Laboratory Personnel
Clinical Laboratory Director
Clinical Laboratory Supervisor
Clinical Laboratory Technician
Clinical Laboratory Technologist
Public Health Director
Public Health Supervisor
Public Health Technologist
Disclosure statements
The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported financial relationships:
- Peter Kavsak, PhD, FCACB, FCCS
- Grant/Research Support: Abbott Laboratories, Ortho Clinical Diagnostics, Randox Laboratories, Roche Diagnostics, Siemens Healthcare Diagnostics
- Consultant Fee: Beckman Coulter, Abbott Point of Care, Quidel, Roche, Siemens Healthcare Diagnostics
- Board/Committee Membership/Advisory Board: Roche Diagnostics, Siemens Healthcare Diagnostics
- Presenter/Speaker: Abbott Laboratories, Siemens Healthcare Diagnostics, Thermo Fisher Scientific
- Intellectual Property/Royalty Income: METHOD OF DETERMINING RISK OF AN ADVERSE CARDIAC EVENT (EP 3 341 723 A1)
The following faculty reported no relevant financial relationships:
- Ruben Bonilla Guerrero, MD, DABMG, FACMG, FADLM, MB(ASCP), NY(CQ), CGMBS
- Sara Rogers, PharmD